AMIT R MEHTA
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
- Where
- CARY, NC
- NPI
- 1740460377
- Received
- $4,309,585 in 5,120 records, 2019 to 2025
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 824 | $807,540 |
| 2024 | General payment | 708 | $635,598 |
| 2023 | General payment | 827 | $705,479 |
| 2022 | General payment | 921 | $725,877 |
| 2021 | General payment | 679 | $522,672 |
| 2020 | General payment | 367 | $349,389 |
| 2019 | General payment | 794 | $563,028 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 829 | $2,834,530 |
| Travel and Lodging | 2,535 | $750,219 |
| Consulting Fee | 123 | $411,552 |
| Honoraria | 53 | $163,326 |
| Food and Beverage | 1,550 | $80,779 |
| Compensation for serving as faculty or as a speaker for a medical education program | 22 | $68,670 |
| Education | 6 | $267 |
| Entertainment | 2 | $238 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-19 | Incyte Corporation | $4,400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-12-19 | Incyte Corporation | $1,650 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-12-18 | PharmaEssentia USA Corporation | $91 | Food and Beverage | In-kind items and services | BESREMI Drug, Oncology | 2025 | |
| 2025-12-17 | PharmaEssentia USA Corporation | $934 | Travel and Lodging | In-kind items and services | BESREMI Drug, Oncology | 2025 | |
| 2025-12-17 | PharmaEssentia USA Corporation | $334 | Travel and Lodging | In-kind items and services | BESREMI Drug, Oncology | 2025 | |
| 2025-12-17 | PharmaEssentia USA Corporation | $244 | Travel and Lodging | In-kind items and services | BESREMI Drug, Oncology | 2025 | |
| 2025-12-15 | PharmaEssentia USA Corporation | $6,700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BESREMI Drug, Oncology | 2025 | |
| 2025-12-15 | PharmaEssentia USA Corporation | $418 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BESREMI Drug, Oncology | 2025 | |
| 2025-12-11 | Geron Corporation | $5,760 | Consulting Fee | Cash or cash equivalent | RYTELO Drug, MYELODYSPLASTIC SYNDROME | 2025 | |
| 2025-12-11 | PharmaEssentia USA Corporation | $589 | Travel and Lodging | In-kind items and services | BESREMI Drug, Oncology | 2025 | |
| 2025-12-11 | PharmaEssentia USA Corporation | $146 | Travel and Lodging | In-kind items and services | BESREMI Drug, Oncology | 2025 | |
| 2025-12-11 | PharmaEssentia USA Corporation | $121 | Food and Beverage | In-kind items and services | BESREMI Drug, Oncology | 2025 | |
| 2025-12-10 | PharmaEssentia USA Corporation | $4,690 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BESREMI Drug, Oncology | 2025 | |
| 2025-12-08 | Janssen Biotech, Inc. | $4,162 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RYBREVANT Drug, Oncology | 2025 | |
| 2025-12-06 | Geron Corporation | $20 | Food and Beverage | In-kind items and services | RYTELO Drug, MYELODYSPLASTIC SYNDROME | 2025 | |
| 2025-12-05 | Rigel Pharmaceuticals, Inc. | $1,755 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TAVALISSE Drug, Hematology | 2025 | |
| 2025-12-05 | Janssen Biotech, Inc. | $577 | Travel and Lodging | In-kind items and services | RYBREVANT Drug, Oncology | 2025 | |
| 2025-12-05 | Geron Corporation | $145 | Food and Beverage | In-kind items and services | RYTELO Drug, MYELODYSPLASTIC SYNDROME | 2025 | |
| 2025-12-05 | GENZYME CORPORATION | $77 | Food and Beverage | In-kind items and services | WAYRILZ Drug, Immunology | 2025 | |
| 2025-12-04 | Janssen Biotech, Inc. | $146 | Food and Beverage | In-kind items and services | RYBREVANT Drug, Oncology | 2025 | |
| 2025-12-04 | Geron Corporation | $44 | Travel and Lodging | Cash or cash equivalent | RYTELO Drug, MYELODYSPLASTIC SYNDROME | 2025 | |
| 2025-12-04 | Geron Corporation | $31 | Food and Beverage | Cash or cash equivalent | RYTELO Drug, MYELODYSPLASTIC SYNDROME | 2025 | |
| 2025-12-04 | Geron Corporation | $20 | Travel and Lodging | Cash or cash equivalent | RYTELO Drug, MYELODYSPLASTIC SYNDROME | 2025 | |
| 2025-12-03 | Incyte Corporation | $5,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-12-03 | Incyte Corporation | $5,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-12-03 | Incyte Corporation | $5,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-12-03 | PharmaEssentia USA Corporation | $1,039 | Travel and Lodging | In-kind items and services | BESREMI Drug, Oncology | 2025 | |
| 2025-12-03 | Incyte Corporation | $56 | Travel and Lodging | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-12-03 | Incyte Corporation | $14 | Food and Beverage | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-12-03 | Incyte Corporation | $13 | Travel and Lodging | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-12-02 | Incyte Corporation | $641 | Travel and Lodging | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-12-02 | Incyte Corporation | $201 | Travel and Lodging | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-12-02 | Incyte Corporation | $70 | Travel and Lodging | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-12-02 | Incyte Corporation | $55 | Food and Beverage | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-12-02 | Incyte Corporation | $21 | Food and Beverage | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-12-02 | Incyte Corporation | $1 | Travel and Lodging | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-11-26 | PharmaEssentia USA Corporation | $1,340 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BESREMI Drug, Oncology | 2025 | |
| 2025-11-25 | Rigel Pharmaceuticals, Inc. | $179 | Travel and Lodging | Cash or cash equivalent | TAVALISSE Drug, Hematology | 2025 | |
| 2025-11-25 | Rigel Pharmaceuticals, Inc. | $101 | Travel and Lodging | Cash or cash equivalent | TAVALISSE Drug, Hematology | 2025 | |
| 2025-11-25 | Rigel Pharmaceuticals, Inc. | $74 | Food and Beverage | Cash or cash equivalent | TAVALISSE Drug, Hematology | 2025 | |
| 2025-11-25 | Rigel Pharmaceuticals, Inc. | $12 | Travel and Lodging | Cash or cash equivalent | TAVALISSE Drug, Hematology | 2025 | |
| 2025-11-25 | Rigel Pharmaceuticals, Inc. | $6 | Travel and Lodging | Cash or cash equivalent | TAVALISSE Drug, Hematology | 2025 | |
| 2025-11-24 | PharmaEssentia USA Corporation | $89 | Travel and Lodging | Cash or cash equivalent | BESREMI Drug, Oncology | 2025 | |
| 2025-11-24 | PharmaEssentia USA Corporation | $4 | Travel and Lodging | Cash or cash equivalent | BESREMI Drug, Oncology | 2025 | |
| 2025-11-20 | Astellas Pharma US Inc | $2,100 | Consulting Fee | Cash or cash equivalent | Padcev Drug, Oncology | 2025 | |
| 2025-11-20 | Incyte Corporation | $825 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Jakafi Drug, Hematology/Oncology | 2025 | |
| 2025-11-19 | Incyte Corporation | $1,650 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-11-19 | Janssen Biotech, Inc. | $555 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RYBREVANT Drug, Oncology | 2025 | |
| 2025-11-19 | Medtronic, Inc. | $230 | Food and Beverage | In-kind items and services | PIPELINE Device, Flow Diversion | 2025 | |
| 2025-11-18 | PharmaEssentia USA Corporation | $6,700 | Consulting Fee | Cash or cash equivalent | BESREMI Drug, Oncology | 2025 | |
| 2025-11-18 | PFIZER INC. | $1,389 | Travel and Lodging | In-kind items and services | TALZENNA Drug, ONCOLOGY | 2025 | |
| 2025-11-18 | Novartis Pharmaceuticals Corporation | $385 | Travel and Lodging | In-kind items and services | PLUVICTO Drug, Oncology | 2025 | |
| 2025-11-18 | PharmaEssentia USA Corporation | $369 | Travel and Lodging | Cash or cash equivalent | BESREMI Drug, Oncology | 2025 | |
| 2025-11-18 | Novartis Pharmaceuticals Corporation | $337 | Travel and Lodging | In-kind items and services | PLUVICTO Drug, Oncology | 2025 | |
| 2025-11-18 | Novartis Pharmaceuticals Corporation | $119 | Food and Beverage | In-kind items and services | PLUVICTO Drug, Oncology | 2025 | |
| 2025-11-18 | PharmaEssentia USA Corporation | $109 | Food and Beverage | Cash or cash equivalent | BESREMI Drug, Oncology | 2025 | |
| 2025-11-18 | PFIZER INC. | $11 | Food and Beverage | In-kind items and services | TALZENNA Drug, ONCOLOGY | 2025 | |
| 2025-11-14 | Astellas Pharma US Inc | $6,020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Xtandi Drug, Oncology | 2025 | |
| 2025-11-14 | PFIZER INC. | $5,050 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TALZENNA Drug, ONCOLOGY | 2025 | |
| 2025-11-14 | Astellas Pharma US Inc | $547 | Travel and Lodging | Cash or cash equivalent | Xtandi Drug, Oncology | 2025 | |
| 2025-11-14 | Astellas Pharma US Inc | $544 | Travel and Lodging | Cash or cash equivalent | Xtandi Drug, Oncology | 2025 | |
| 2025-11-14 | Astellas Pharma US Inc | $27 | Food and Beverage | In-kind items and services | Xtandi Drug, Oncology | 2025 | |
| 2025-11-13 | Incyte Corporation | $807 | Travel and Lodging | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-11-13 | Incyte Corporation | $277 | Travel and Lodging | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-11-13 | Incyte Corporation | $168 | Travel and Lodging | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-11-13 | Incyte Corporation | $124 | Food and Beverage | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-11-13 | Janssen Biotech, Inc. | $50 | Travel and Lodging | In-kind items and services | RYBREVANT Drug, Oncology | 2025 | |
| 2025-11-13 | Incyte Corporation | $19 | Food and Beverage | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-11-13 | Incyte Corporation | $10 | Food and Beverage | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-11-13 | Incyte Corporation | $7 | Food and Beverage | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-11-12 | Incyte Corporation | $686 | Travel and Lodging | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-11-12 | Incyte Corporation | $472 | Travel and Lodging | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-11-12 | Incyte Corporation | $282 | Travel and Lodging | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-11-12 | Incyte Corporation | $124 | Food and Beverage | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-11-12 | Incyte Corporation | $46 | Food and Beverage | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-11-12 | Pharming Healthcare, Inc. | $31 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-11-12 | Incyte Corporation | $23 | Travel and Lodging | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-11-12 | Pharming Healthcare, Inc. | $23 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-11-12 | Pharming Healthcare, Inc. | $20 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-11-12 | Janssen Biotech, Inc. | $19 | Travel and Lodging | In-kind items and services | RYBREVANT Drug, Oncology | 2025 | |
| 2025-11-11 | Pharming Healthcare, Inc. | $7,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-11-11 | Pharming Healthcare, Inc. | $256 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-11-11 | Pharming Healthcare, Inc. | $234 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-11-11 | Pharming Healthcare, Inc. | $121 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-11-11 | Pharming Healthcare, Inc. | $29 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-11-11 | Pharming Healthcare, Inc. | $26 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-11-11 | Pharming Healthcare, Inc. | $25 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-11-11 | Pharming Healthcare, Inc. | $21 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-11-11 | Pharming Healthcare, Inc. | $21 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-11-11 | Pharming Healthcare, Inc. | $15 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-11-11 | Pharming Healthcare, Inc. | $13 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-11-10 | PharmaEssentia USA Corporation | $1,340 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BESREMI Drug, Oncology | 2025 | |
| 2025-11-10 | PharmaEssentia USA Corporation | $1,340 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BESREMI Drug, Oncology | 2025 | |
| 2025-11-10 | PFIZER INC. | $106 | Food and Beverage | In-kind items and services | TALZENNA Drug, ONCOLOGY | 2025 | |
| 2025-11-06 | GENZYME CORPORATION | $6,794 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | WAYRILZ Drug, Immunology | 2025 | |
| 2025-11-06 | GENZYME CORPORATION | $984 | Travel and Lodging | In-kind items and services | WAYRILZ Drug, Immunology | 2025 | |
| 2025-11-06 | Geron Corporation | $173 | Travel and Lodging | Cash or cash equivalent | RYTELO Drug, MYELODYSPLASTIC SYNDROME | 2025 | |
| 2025-11-06 | GENZYME CORPORATION | $110 | Food and Beverage | In-kind items and services | WAYRILZ Drug, Immunology | 2025 | |
| 2025-11-06 | Geron Corporation | $66 | Food and Beverage | Cash or cash equivalent | RYTELO Drug, MYELODYSPLASTIC SYNDROME | 2025 | |
| 2025-11-06 | Geron Corporation | $39 | Travel and Lodging | Cash or cash equivalent | RYTELO Drug, MYELODYSPLASTIC SYNDROME | 2025 | |
| 2025-11-06 | Geron Corporation | $20 | Food and Beverage | Cash or cash equivalent | RYTELO Drug, MYELODYSPLASTIC SYNDROME | 2025 | |
| 2025-11-06 | GENZYME CORPORATION | $7 | Food and Beverage | Cash or cash equivalent | WAYRILZ Drug, Immunology | 2025 | |
| 2025-11-05 | GENZYME CORPORATION | $2,265 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | WAYRILZ Drug, Immunology | 2025 | |
| 2025-11-05 | Geron Corporation | $41 | Food and Beverage | Cash or cash equivalent | RYTELO Drug, MYELODYSPLASTIC SYNDROME | 2025 | |
| 2025-11-05 | Geron Corporation | $32 | Travel and Lodging | Cash or cash equivalent | RYTELO Drug, MYELODYSPLASTIC SYNDROME | 2025 | |
| 2025-11-05 | Geron Corporation | $30 | Food and Beverage | Cash or cash equivalent | RYTELO Drug, MYELODYSPLASTIC SYNDROME | 2025 | |
| 2025-11-05 | Geron Corporation | $15 | Food and Beverage | Cash or cash equivalent | RYTELO Drug, MYELODYSPLASTIC SYNDROME | 2025 | |
| 2025-11-05 | Geron Corporation | $10 | Travel and Lodging | Cash or cash equivalent | RYTELO Drug, MYELODYSPLASTIC SYNDROME | 2025 | |
| 2025-10-30 | GENZYME CORPORATION | $2,265 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | WAYRILZ Drug, Immunology | 2025 | |
| 2025-10-29 | PharmaEssentia USA Corporation | $5,360 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BESREMI Drug, Oncology | 2025 | |
| 2025-10-29 | EMD Serono, Inc. | $3,450 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-10-29 | PharmaEssentia USA Corporation | $3,350 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BESREMI Drug, Oncology | 2025 | |
| 2025-10-29 | PharmaEssentia USA Corporation | $74 | Travel and Lodging | Cash or cash equivalent | BESREMI Drug, Oncology | 2025 | |
| 2025-10-29 | Rigel Pharmaceuticals, Inc. | $70 | Food and Beverage | In-kind items and services | TAVALISSE Drug, Hematology | 2025 | |
| 2025-10-29 | PharmaEssentia USA Corporation | $45 | Food and Beverage | Cash or cash equivalent | BESREMI Drug, Oncology | 2025 | |
| 2025-10-29 | PharmaEssentia USA Corporation | $37 | Food and Beverage | Cash or cash equivalent | BESREMI Drug, Oncology | 2025 | |
| 2025-10-29 | PharmaEssentia USA Corporation | $22 | Travel and Lodging | Cash or cash equivalent | BESREMI Drug, Oncology | 2025 | |
| 2025-10-28 | Geron Corporation | $3,840 | Consulting Fee | Cash or cash equivalent | IMETELSTAT Drug, HEMATOLOGY | 2025 | |
| 2025-10-28 | Geron Corporation | $594 | Travel and Lodging | Cash or cash equivalent | IMETELSTAT Drug, HEMATOLOGY | 2025 | |
| 2025-10-28 | Rigel Pharmaceuticals, Inc. | $402 | Travel and Lodging | In-kind items and services | TAVALISSE Drug, Hematology | 2025 | |
| 2025-10-27 | PharmaEssentia USA Corporation | $593 | Travel and Lodging | In-kind items and services | BESREMI Drug, Oncology | 2025 | |
| 2025-10-27 | PharmaEssentia USA Corporation | $116 | Travel and Lodging | In-kind items and services | BESREMI Drug, Oncology | 2025 | |
| 2025-10-25 | Geron Corporation | $276 | Travel and Lodging | Cash or cash equivalent | IMETELSTAT Drug, HEMATOLOGY | 2025 | |
| 2025-10-25 | Geron Corporation | $54 | Food and Beverage | In-kind items and services | IMETELSTAT Drug, HEMATOLOGY | 2025 | |
| 2025-10-25 | Geron Corporation | $22 | Food and Beverage | In-kind items and services | IMETELSTAT Drug, HEMATOLOGY | 2025 | |
| 2025-10-25 | Geron Corporation | $18 | Food and Beverage | In-kind items and services | IMETELSTAT Drug, HEMATOLOGY | 2025 | |
| 2025-10-24 | PFIZER INC. | $1,315 | Travel and Lodging | In-kind items and services | PADCEV Biological, ONCOLOGY | 2025 | |
| 2025-10-24 | Incyte Corporation | $870 | Travel and Lodging | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-10-24 | Incyte Corporation | $63 | Travel and Lodging | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-10-24 | Incyte Corporation | $57 | Food and Beverage | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-10-24 | Incyte Corporation | $16 | Food and Beverage | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-10-24 | Incyte Corporation | $10 | Travel and Lodging | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-10-23 | PharmaEssentia USA Corporation | $125 | Food and Beverage | In-kind items and services | BESREMI Drug, Oncology | 2025 | |
| 2025-10-22 | Geron Corporation | $7,360 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RYTELO Drug, MYELODYSPLASTIC SYNDROME | 2025 | |
| 2025-10-22 | Pharming Healthcare, Inc. | $2,400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JOENJA Drug, APDS | 2025 | |
| 2025-10-22 | Geron Corporation | $2,240 | Consulting Fee | Cash or cash equivalent | IMETELSTAT Drug, HEMATOLOGY | 2025 | |
| 2025-10-22 | Novartis Pharmaceuticals Corporation | $700 | Consulting Fee | Cash or cash equivalent | PLUVICTO Drug, Oncology | 2025 | |
| 2025-10-21 | Aveo Pharmaceuticals, Inc. | $5,445 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | FOTIVDA Drug, Oncology | 2025 | |
| 2025-10-21 | Astellas Pharma US Inc | $5,160 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Xtandi Drug, Oncology | 2025 | |
| 2025-10-21 | Astellas Pharma US Inc | $697 | Travel and Lodging | Cash or cash equivalent | Xtandi Drug, Oncology | 2025 | |
| 2025-10-21 | Astellas Pharma US Inc | $78 | Food and Beverage | In-kind items and services | Xtandi Drug, Oncology | 2025 | |
| 2025-10-21 | PFIZER INC. | $6 | Food and Beverage | In-kind items and services | PADCEV Biological, ONCOLOGY | 2025 | |
| 2025-10-20 | Rigel Pharmaceuticals, Inc. | $5,148 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TAVALISSE Drug, Hematology | 2025 | |
| 2025-10-20 | PFIZER INC. | $5,050 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | PADCEV Biological, ONCOLOGY | 2025 | |
| 2025-10-20 | Rigel Pharmaceuticals, Inc. | $173 | Travel and Lodging | Cash or cash equivalent | TAVALISSE Drug, Hematology | 2025 | |
| 2025-10-20 | Rigel Pharmaceuticals, Inc. | $75 | Food and Beverage | Cash or cash equivalent | TAVALISSE Drug, Hematology | 2025 | |
| 2025-10-20 | Rigel Pharmaceuticals, Inc. | $67 | Food and Beverage | Cash or cash equivalent | TAVALISSE Drug, Hematology | 2025 | |
| 2025-10-20 | Rigel Pharmaceuticals, Inc. | $33 | Travel and Lodging | Cash or cash equivalent | TAVALISSE Drug, Hematology | 2025 | |
| 2025-10-20 | Rigel Pharmaceuticals, Inc. | $32 | Travel and Lodging | Cash or cash equivalent | TAVALISSE Drug, Hematology | 2025 | |
| 2025-10-20 | Rigel Pharmaceuticals, Inc. | $14 | Travel and Lodging | Cash or cash equivalent | TAVALISSE Drug, Hematology | 2025 | |
| 2025-10-20 | Rigel Pharmaceuticals, Inc. | $14 | Travel and Lodging | Cash or cash equivalent | TAVALISSE Drug, Hematology | 2025 | |
| 2025-10-20 | Rigel Pharmaceuticals, Inc. | $11 | Travel and Lodging | Cash or cash equivalent | TAVALISSE Drug, Hematology | 2025 | |
| 2025-10-20 | Rigel Pharmaceuticals, Inc. | $0 | Travel and Lodging | Cash or cash equivalent | TAVALISSE Drug, Hematology | 2025 | |
| 2025-10-16 | Astellas Pharma US Inc | $5,160 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Padcev Drug, Oncology | 2025 | |
| 2025-10-16 | Astellas Pharma US Inc | $1,156 | Travel and Lodging | Cash or cash equivalent | Padcev Drug, Oncology | 2025 | |
| 2025-10-16 | Astellas Pharma US Inc | $114 | Food and Beverage | In-kind items and services | Padcev Drug, Oncology | 2025 | |
| 2025-10-15 | PFIZER INC. | $75 | Food and Beverage | In-kind items and services | PADCEV Biological, ONCOLOGY | 2025 | |
| 2025-10-14 | PFIZER INC. | $1,479 | Travel and Lodging | In-kind items and services | PADCEV Biological, ONCOLOGY | 2025 | |
| 2025-10-14 | Geron Corporation | $466 | Travel and Lodging | In-kind items and services | RYTELO Drug, MYELODYSPLASTIC SYNDROME | 2025 | |
| 2025-10-14 | Pharming Healthcare, Inc. | $83 | Food and Beverage | In-kind items and services | RUCONEST Biological, BIOLOGIC | 2025 | |
| 2025-10-11 | PFIZER INC. | $1,413 | Travel and Lodging | In-kind items and services | PADCEV Biological, ONCOLOGY | 2025 | |
| 2025-10-10 | Janssen Biotech, Inc. | $1,110 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RYBREVANT Drug, Oncology | 2025 | |
| 2025-10-09 | Astellas Pharma US Inc | $6,020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Padcev Drug, Oncology | 2025 | |
| 2025-10-09 | PFIZER INC. | $5,050 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | PADCEV Biological, ONCOLOGY | 2025 | |
| 2025-10-09 | Astellas Pharma US Inc | $631 | Travel and Lodging | Cash or cash equivalent | Padcev Drug, Oncology | 2025 | |
| 2025-10-09 | Astellas Pharma US Inc | $365 | Travel and Lodging | Cash or cash equivalent | Padcev Drug, Oncology | 2025 | |
| 2025-10-09 | Astellas Pharma US Inc | $335 | Travel and Lodging | Cash or cash equivalent | Padcev Drug, Oncology | 2025 | |
| 2025-10-09 | Astellas Pharma US Inc | $108 | Food and Beverage | In-kind items and services | Padcev Drug, Oncology | 2025 | |
| 2025-10-08 | Geron Corporation | $7,360 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RYTELO Drug, MYELODYSPLASTIC SYNDROME | 2025 | |
| 2025-10-08 | Rigel Pharmaceuticals, Inc. | $5,148 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TAVALISSE Drug, Hematology | 2025 | |
| 2025-10-08 | Geron Corporation | $21 | Travel and Lodging | Cash or cash equivalent | RYTELO Drug, MYELODYSPLASTIC SYNDROME | 2025 | |
| 2025-10-08 | Geron Corporation | $19 | Food and Beverage | Cash or cash equivalent | RYTELO Drug, MYELODYSPLASTIC SYNDROME | 2025 | |
| 2025-10-08 | Geron Corporation | $17 | Food and Beverage | Cash or cash equivalent | RYTELO Drug, MYELODYSPLASTIC SYNDROME | 2025 | |
| 2025-10-08 | Geron Corporation | $10 | Food and Beverage | Cash or cash equivalent | RYTELO Drug, MYELODYSPLASTIC SYNDROME | 2025 | |
| 2025-10-08 | GENZYME CORPORATION | $7 | Food and Beverage | In-kind items and services | SARCLISA Biological, Oncology | 2025 | |
| 2025-10-08 | Geron Corporation | $1 | Travel and Lodging | Cash or cash equivalent | RYTELO Drug, MYELODYSPLASTIC SYNDROME | 2025 | |
| 2025-10-07 | Incyte Corporation | $5,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-10-07 | PFIZER INC. | $12 | Food and Beverage | In-kind items and services | PADCEV Biological, ONCOLOGY | 2025 | |
| 2025-10-07 | PFIZER INC. | $5 | Food and Beverage | In-kind items and services | PADCEV Biological, ONCOLOGY | 2025 | |
| 2025-10-06 | PharmaEssentia USA Corporation | $6,700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BESREMI Drug, Oncology | 2025 | |
| 2025-10-06 | PFIZER INC. | $5,050 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | PADCEV Biological, ONCOLOGY | 2025 | |
| 2025-10-06 | PharmaEssentia USA Corporation | $62 | Travel and Lodging | Cash or cash equivalent | BESREMI Drug, Oncology | 2025 | |
| 2025-10-06 | PharmaEssentia USA Corporation | $36 | Food and Beverage | Cash or cash equivalent | BESREMI Drug, Oncology | 2025 | |
| 2025-10-06 | PharmaEssentia USA Corporation | $18 | Food and Beverage | Cash or cash equivalent | BESREMI Drug, Oncology | 2025 | |
| 2025-10-04 | Rigel Pharmaceuticals, Inc. | $1,033 | Travel and Lodging | In-kind items and services | TAVALISSE Drug, Hematology | 2025 | |
| 2025-10-04 | Rigel Pharmaceuticals, Inc. | $276 | Travel and Lodging | In-kind items and services | TAVALISSE Drug, Hematology | 2025 | |
| 2025-10-03 | Merck Sharp & Dohme LLC | $14 | Food and Beverage | In-kind items and services | LYNPARZA Biological, ONCOLOGY | 2025 | |
| 2025-10-02 | PFIZER INC. | $124 | Food and Beverage | In-kind items and services | PADCEV Biological, ONCOLOGY | 2025 | |
| 2025-10-01 | PFIZER INC. | $96 | Food and Beverage | In-kind items and services | PADCEV Biological, ONCOLOGY | 2025 | |
| 2025-09-30 | Incyte Corporation | $703 | Travel and Lodging | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-09-30 | Incyte Corporation | $457 | Travel and Lodging | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-09-30 | Incyte Corporation | $154 | Travel and Lodging | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-09-30 | Incyte Corporation | $148 | Travel and Lodging | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-09-30 | Incyte Corporation | $124 | Food and Beverage | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-09-30 | Incyte Corporation | $63 | Travel and Lodging | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-09-30 | Incyte Corporation | $51 | Food and Beverage | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-09-30 | Incyte Corporation | $18 | Food and Beverage | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-09-30 | Incyte Corporation | $6 | Food and Beverage | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-09-29 | PharmaEssentia USA Corporation | $363 | Travel and Lodging | In-kind items and services | BESREMI Drug, Oncology | 2025 | |
| 2025-09-29 | PharmaEssentia USA Corporation | $261 | Travel and Lodging | In-kind items and services | BESREMI Drug, Oncology | 2025 |
The latest 200 records of 5,120.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Cary, NC, county Wake County, NC, state North Carolina; placed by its city name.
| Measure | Place (city or town) Cary, NC | County Wake County, NC | State North Carolina |
|---|---|---|---|
| Population B01003 | 179,306 | 1,178,653 | 10,730,404 |
| Population, 2020 census P1 | 174,721 | 1,129,410 | 10,439,388 |
| Median age B01002 | 40.2 | 37.3 | 39.1 |
| Under 18 B01001 | 23.4% | 23.0% | 21.8% |
| 65 and over B01001 | 14.1% | 12.9% | 17.2% |
| Households B11001 | 69,710 | 460,175 | 4,282,345 |
| Foreign born B05002 | 23.9% | 15.3% | 9.1% |
| Median household income B19013 | $134,905 | $105,768 | $72,388 |
| Median family income B19113 | $166,301 | $132,741 | $90,290 |
| Per capita income B19301 | $67,409 | $55,448 | $41,385 |
| Poverty rate B17001 | 5.7% | 8.1% | 13.0% |
| Unemployment rate B23025 | 3.5% | 4.1% | 4.7% |
| Civilian labor force B23025 | 98,795 | 655,135 | 5,336,863 |
| Mean commute (minutes) B08013 | 22.5 | 25.1 | 25.1 |
| Bachelor's degree or higher B15003 | 70.5% | 57.2% | 35.7% |
| Housing units B25001 | 73,795 | 496,047 | 4,895,668 |
| Owner-occupied B25003 | 66.6% | 64.1% | 66.6% |
| Renters B25003 | 33.4% | 35.9% | 33.4% |
| Median home value B25077 | $580,200 | $461,300 | $288,900 |
| Median gross rent B25064 | $1,738 | $1,623 | $1,228 |
| White, not Hispanic B03002 | 56.7% | 56.2% | 60.0% |
| Black B03002 | 7.6% | 18.5% | 20.0% |
| Hispanic or Latino B03002 | 9.5% | 11.6% | 11.3% |
| Asian B03002 | 20.3% | 8.5% | 3.3% |
| American Indian and Alaska Native B03002 | 0.1% | 0.2% | 0.8% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Cary, NC.
Comments